Google
Featured Topics
New to oneAMYLOIDOSISvoice? Activate your membership!
Whether you’re a first-time visitor or someone already well familiar with our growing collection of the best and most trustworthy amyloidosis resources from across the web, there’s a lot more to oneAMYLOIDOSISvoice. But it’s exclusively available to our registered members. Registering as a member is quick and easy, and best of all, it’s FREE. We hope you’ll jump in and explore all that oneAMYLOIDOSISvoice has to offer.
| Visitor | Member | |
|---|---|---|
| Access to Trusted Resources & Diagnosis Educator sections |  |
|
| Access to Clinical Trial Locator |  |
|
| Access to Social Wall (Community Discussion) | |
|
| rareTeams Private Groups | |
|
| Direct Messaging | |
|
| Weekly Activity E-mails | |
|
| Bookmarking of Resources & Conversations | |
|
| Customized Member Profile | |
|
Join the conversation
The Social Wall is the heart of oneAMYLOIDOSISvoice — where you can share your thoughts, ask questions and discuss the latest amyloidosis news and research, as well as post photos, videos, or links.
Create your free member account or log in to join the conversation!
Hot Topics
Featured Article
More helpful articles
- Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
- Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
- How Did Transthyretin Amyloid Cardiomyopathy Progress in Patients Who Took Placebo in the Study ATTR-ACT? A Plain Language Summary
- Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
Featured Infographics
News & Resources
Read more
Diagnosis Educator
What Are the Financial Assistance Programs Available to US Amyloidosis Patients?
What Are the Complications Associated With Amyloidosis?
- Obesity is a Significant Susceptibility Factor for Idiopathic AA Amyloidosis
- Depression and Anxiety in Patients With AL Amyloidosis as Assessed by the SF-36 Questionnaire
- The Patient’s Perspective on the Symptom and Everyday Life Impact of AL Amyloidosis
- 8 Ways Amyloidosis Affects the Body
- Complications of Untreated Amyloidosis
- Dry Mouth in Amyloidosis
- Renal Amyloidosis by Dr. Jo Abraham
- AL Amyloidosis and the Gut by Dr. John Clarke
- AL Amyloidosis and the Kidney
- Diarrhea and AL Amyloidosis
- Health-Related Quality of Life in Hereditary Transthyretin Amyloidosis Polyneuropathy: A Prospective, Observational Study
What Is the Treatment for Amyloidosis?
- Sorrento STI-6129 ADC Initial Human Study Update
- Introduction & Discussion: Andromeda Drug Trial (daratumumab) and Related Topics
- How to Treat AL Amyloidosis in 2020?
- Treatment
- Treatment by Type
- Treatment Options
- Pfizer's Vyndaqel and Vyndamax (tafamidis) Treatments for TTR amyloidosis
- Wild Type ATTR (ATTRwt)
- AA Amyloidosis Management
Featured Poll
The Onevoice Difference
Trusted Resources
Everything you’ll find on this site is curated by professional researchers who are guided by our councils of healthcare professionals, advocates, patients, and caregivers. We provide only the best, mosttrusted rare-disease resources.
Strong Partnerships
This onevoice site is maintained in collaboration with Amyloidosis Support Groups. They help us keep up-to-date with the fast-changing world of rare disease and ensure that we always meet the needs of the community.
Safe Community Space
Our Social Wall and private rareTeams groups are members-only features, with the aim of providing a safe, secure space for community-driven conversations, moderated by a disease-knowledgeable community leader.
Want to learn more?
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
oneAMYLOIDOSISvoice Working Group
-
Kevin Michael Alexander, MD
Instructor, Cardiovascular Institute
Cardiovascular Medicine
Stanford University -
Chafic Karam, MD
Neurologist
Penn Neuroscience Center
Perelman Center for Advanced Medicine -
David Jennings
Founder
fibrinogenamyloidosis.com (Blog) -
Jeffrey Allan Zonder, MD
Professor
Department of Oncology
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine -
Katie Agre, MS, LCGC
Licensed Genetic Counselor
Department of Clinical Genomics
Mayo Clinic -
Carolyn Foulston
Advocate -
Sara Horst, MD, MPH
Associate Professor
Division of Gastroenterology, Hepatology, & Nutrition
Vanderbilt University Medical Center
1030C MRB IV, 2215 Garland Avenue -
Cara A. Rosenbaum, MD
Assistant Professor of Medicine
Division of Hematology
and Medical Oncology
Weill Cornell Medicine
Staff Oncologist
New York-Presbyterian Hospital -
Kelsey Barrell, MD
Assistant Professor
Neuromuscular Medicine
Department of Neurology, University of Utah
